abstract |
The present invention relates to a pharmaceutical product for hemophilia and asthmatic bronchitis treatment comprising a natural polymer composed by a molecular chain comprising of 1 to 5000 monomers, being said polymer classified according to the set below, with its related acting ratios: a) β-1,4-poly-N-acetyl-D-glucosamine, with a fractionated molecular chain ratio of 0 % to 100 %; and b) β-1,4-poly-D-glucosamine, with a fractionated molecular chain ratio of 0 % to 100 %. |